Filtered By:
Drug: Methotrexate
Management: Healthcare Costs
This page shows you your search results in order of date.
Order by Relevance | Date
Total 53 results found since Jan 2013.
Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs
CONCLUSIONS: According to our estimates, around 10% RA patients not currently treated with biotechnological agents are eligible for such therapies, highlighting a trend of under-use in clinical practice for RA management.PMID:33874642 | DOI:10.4081/reumatismo.2021.1329
Source: Reumatismo - April 20, 2021 Category: Rheumatology Authors: L Degli Esposti V Perrone D Sangiorgi L Sinigaglia Source Type: research
